SWM
ATNM icon

Spire Wealth Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Spire Wealth Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,800
Closed -$11K – 2523
2021
Q4 		$11K Buy
+1,800
New +$13.5K ﹤0.01% 2334
2021
Q2 		– Sell
-1,800
Closed -$15K – 2594
2021
Q1 		$15K Buy
+1,800
New +$15.3K ﹤0.01% 2253

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Spire Wealth Management's ATNM Position: Q1 2022 in Review

Spire Wealth Management sold out of Actinium Pharmaceuticals (ATNM) in Q1 2022, closing a stake of 1,800 shares — an estimated $11K sold.

Spire Wealth Management first reported a position in ATNM in Q1 2021 and held it in 2 quarters. The position peaked at $15K in Q1 2021. 38 funds tracked by Wall St. Rank hold ATNM as of Q1 2022.

  • Spire Wealth Management reported no remaining Actinium Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Spire Wealth Management sold 1,800 Actinium Pharmaceuticals shares in Q1 2022, an estimated $11K.
  • Spire Wealth Management first reported a position in Actinium Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Spire Wealth Management's Actinium Pharmaceuticals position peaked at $15K in Q1 2021.
  • 38 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2022.

Based on Spire Wealth Management's 13F filing for Q1 2022, filed 18 Apr 2022.